What are the NCCN guidelines for neoadjuvant therapy for pancreatic cancer?

Updated: Mar 07, 2019
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print
Answer

Like ESMO, NCCN recommends considering preoperative neoadjuvant therapy for patients with resectable or borderline resectable tumors, but notes that "there is limited evidence to recommend specific neoadjuvant regimens off-study, and practices vary with regard to the use of chemotherapy and radiation." NCCN recommendations on neoadjuvant therapy in pancreatic carcinoma are as follows [2] :

  • Consult with a high-volume center when neoadjuvant therapy is being considered\.
  • If neoadjuvant therapy is recommended, treat at or coordinate through a high-volume center, when feasible. 
  • Participation in a clinical trial is encouraged.
  •  Subsequent chemoradiation is sometimes included.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!